© 2005 Oxford University Press
NEWS |
New Office and New Leader Aim To Streamline FDA Cancer Drug Review Process
| The first 150 words of the full text of this article appear below. |
By late this summer, the U.S. Food and Drug Administration is expected to put both a new face and a new place on its review of cancer drugs.
By August, the first phase of the FDA's new campus at White Oaks, Md., will be open, and one building will house the new Office of Oncology Drug Products (ODP). At the helm will be Richard Pazdur, M.D., head of the FDA's Division of Oncology Drug Products, who was named to head the new office on April 22.
| |||||||||||
The new office represents a major change in the way that the FDA has historically reviewed cancer drug applications—a move toward centralization. The FDA says that substantial changes to its organizational structure will provide a stronger and more consistent approach to the review process for drugs and most therapeutic biologics used to diagnose, treat, and prevent cancer. It will work to
Change Amid Controversy
In the Hot Seat